ImmunoMind
Private Company
Total funding raised: $2.5M
Overview
ImmunoMind is an AI-driven biotech startup building an open-source ecosystem for personalized immunotherapy and vaccine design. Its technology platform, rooted in the widely-used Immunarch bioinformatics tool, applies machine learning to single-cell and bulk multi-omics data to analyze immune cell populations, with a strong initial focus on improving CAR-T cell therapy development. The company targets biopharma partners, biotech startups, and research institutions, aiming to de-risk drug discovery, enhance clinical trial success, and fuel novel biomarker discovery. As a pre-revenue platform company, its growth is tied to strategic partnerships with major pharmaceutical and academic entities.
Technology Platform
AI-powered open-source ecosystem for immune system analysis and biomarker discovery from multi-omics data, built around the Immunarch bioinformatics tool. The platform uses machine learning to model drug-immune system interactions, predict therapy efficacy, stratify patients, and analyze immune cell characteristics (e.g., exhaustion, heterogeneity, differentiation) for therapy design and optimization.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
ImmunoMind competes in the AI-for-drug-discovery space, facing broad competitors like Recursion, Exscientia, and Insilico Medicine that have immunology programs. It also faces niche competitors focused on computational immunology and single-cell data analysis. Its key differentiator is its deep specialization in immune repertoire analysis (via Immunarch) and its focused applications for cell therapy optimization, which may provide an edge over more generalized platforms.